Company intelligence / Profile preview

LEROY Biotech

Saint-Orens-de-Gameville, Occitanie, France

Ownership: Private
Development stage: Other

Overview

LEROY Biotech is a French biotechnology company specializing in the development and manufacturing of advanced electroporation systems for medical and veterinary applications. The company provides high-performance pulse generators and electrodes designed for electrochemotherapy and gene electrotransfer, facilitating the delivery of drugs and genetic material into cells. Their technology is primarily utilized in oncology for the treatment of cutaneous and subcutaneous tumors, as well as in research for DNA vaccination and cell therapy. LEROY Biotech serves both the clinical market and the life sciences research community with standardized and customized electroporation solutions.

Therapeutic areas: OncologyDermatologyInfectious Diseases
Modalities: Gene therapyDeviceElectroporation
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on LEROY Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LEROY Biotech.

Explore the full profile